Chad V. Pecot

7.8k total citations · 1 hit paper
59 papers, 2.9k citations indexed

About

Chad V. Pecot is a scholar working on Molecular Biology, Cancer Research and Oncology. According to data from OpenAlex, Chad V. Pecot has authored 59 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Molecular Biology, 23 papers in Cancer Research and 22 papers in Oncology. Recurrent topics in Chad V. Pecot's work include MicroRNA in disease regulation (13 papers), Cancer-related molecular mechanisms research (11 papers) and Lung Cancer Treatments and Mutations (8 papers). Chad V. Pecot is often cited by papers focused on MicroRNA in disease regulation (13 papers), Cancer-related molecular mechanisms research (11 papers) and Lung Cancer Treatments and Mutations (8 papers). Chad V. Pecot collaborates with scholars based in United States, Russia and China. Chad V. Pecot's co-authors include Anil K. Sood, Gabriel Lopez‐Berestein, Robert L. Coleman, George A. Calin, Rajesha Rupaimoole, Jillian L. Perry, J. Christopher Luft, Joseph M. DeSimone, Kevin Reuter and Cristian Rodriguez‐Aguayo and has published in prestigious journals such as Journal of Clinical Investigation, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Chad V. Pecot

56 papers receiving 2.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

RNA interference in the clinic: challenges and future directions

2010 654 citations Chad V. Pecot, George A. Calin et al. Nature reviews. Cancer profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Chad V. Pecot United States	26	1.8k	1.1k	865	415	389	59	2.9k
Kyoko Hida Japan	34	2.5k 1.4×	1.3k 1.2×	956 1.1×	460 1.1×	368 0.9×	65	3.5k
Pilar de la Puente United States	22	1.2k 0.7×	855 0.8×	717 0.8×	609 1.5×	324 0.8×	50	2.7k
Zhuan Zhou China	32	2.0k 1.1×	635 0.6×	698 0.8×	279 0.7×	371 1.0×	81	3.0k
Jihui Hao China	32	1.4k 0.8×	792 0.7×	1.2k 1.4×	434 1.0×	590 1.5×	117	3.1k
Feda Azab United States	26	2.5k 1.4×	1.6k 1.5×	1.1k 1.2×	459 1.1×	661 1.7×	77	4.3k
Leticia Campo United Kingdom	23	1.4k 0.8×	1.1k 1.0×	763 0.9×	293 0.7×	300 0.8×	47	2.5k
Pamela A. Trail United States	29	1.7k 1.0×	521 0.5×	1.5k 1.7×	248 0.6×	474 1.2×	61	3.7k
Danilo Marimpietri Italy	30	1.5k 0.9×	459 0.4×	578 0.7×	293 0.7×	412 1.1×	67	2.6k
Jennifer E. Koblinski United States	27	1.3k 0.7×	752 0.7×	829 1.0×	348 0.8×	222 0.6×	71	2.7k
Róisín M. Dwyer Ireland	31	1.8k 1.0×	1.2k 1.1×	829 1.0×	332 0.8×	291 0.7×	68	3.2k

Countries citing papers authored by Chad V. Pecot

Since Specialization

Citations

This map shows the geographic impact of Chad V. Pecot's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chad V. Pecot with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chad V. Pecot more than expected).

Fields of papers citing papers by Chad V. Pecot

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chad V. Pecot. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chad V. Pecot. The network helps show where Chad V. Pecot may publish in the future.

Co-authorship network of co-authors of Chad V. Pecot

This figure shows the co-authorship network connecting the top 25 collaborators of Chad V. Pecot. A scholar is included among the top collaborators of Chad V. Pecot based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chad V. Pecot. Chad V. Pecot is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Edatt, Lincy, Salma H. Azam, Jin S. Im, et al.. (2025). Inverted chimeric RNAi molecules synergistically cotarget MYC and KRAS in KRAS-driven cancers. Journal of Clinical Investigation. 135(19). 1 indexed citations

2.

Stover, Angela M., Allison M. Deal, Ashley A. Weiner, et al.. (2025). Feasibility, Acceptability, and Utility of Remote Patient-Reported Outcomes Monitoring in Patients With Lung Cancer: A Moovcare© Study. Clinical Lung Cancer. 26(8). e660–e669.e1.

3.

Edatt, Lincy, Danyan Li, Andrew C. Dudley, & Chad V. Pecot. (2025). Diverse roles of quaking in endothelial cell biology. Angiogenesis. 29(1). 4–4.

4.

Kim, Dae Joong, Patcharin Pramoonjago, Jay W. Fox, et al.. (2023). Periostin+ Stromal Cells Guide Lymphovascular Invasion by Cancer Cells. Cancer Research. 83(13). 2105–2122. 12 indexed citations

5.

Im, Jin S., et al.. (2023). P2.11-03 Synergistic Co-Targeting Of MYC And KRAS In Lung Cancer By Novel Ligand-Directed Inverted Chimeric RNAi Molecules. Journal of Thoracic Oncology. 18(11). S360–S361. 1 indexed citations

6.

Murphy, Ryan M., Jason Tasoulas, Alessandro Porrello, et al.. (2022). Tumor Cell Extrinsic Synaptogyrin 3 Expression as a Diagnostic and Prognostic Biomarker in Head and Neck Cancer. Cancer Research Communications. 2(9). 987–1004. 1 indexed citations

7.

Papke, Bjoern, Salma H. Azam, Pradeep S. Pallan, et al.. (2021). Silencing of Oncogenic KRAS by Mutant-Selective Small Interfering RNA. ACS Pharmacology & Translational Science. 4(2). 703–712. 10 indexed citations

8.

Deveaux, April, Tyler A. Allen, Muthana Al Abo, et al.. (2021). RNA splicing and aggregate gene expression differences in lung squamous cell carcinoma between patients of West African and European ancestry. Lung Cancer. 153. 90–98. 5 indexed citations

9.

Vinod, Natasha, Duhyeong Hwang, Salma H. Azam, et al.. (2020). High-capacity poly(2-oxazoline) formulation of TLR 7/8 agonist extends survival in a chemo-insensitive, metastatic model of lung adenocarcinoma. Science Advances. 6(25). eaba5542–eaba5542. 50 indexed citations

10.

Lou, Yanyan, Chad V. Pecot, Hai T. Tran, et al.. (2015). Germline Mutation of T790M and Dual/Multiple EGFR Mutations in Patients With Lung Adenocarcinoma. Clinical Lung Cancer. 17(2). e5–e11. 39 indexed citations

11.

Seviour, Elena G., Vishal Sehgal, Yue Lu, et al.. (2015). Functional proteomics identifies miRNAs to target a p27/Myc/phospho-Rb signature in breast and ovarian cancer. Oncogene. 35(6). 691–701. 48 indexed citations

12.

Bottsford-Miller, Justin, Hyun Jin Choi, Heather J. Dalton, et al.. (2014). Differential Platelet Levels Affect Response to Taxane-Based Therapy in Ovarian Cancer. Clinical Cancer Research. 21(3). 602–610. 73 indexed citations

13.

Beucken, Twan van den, Elizabeth Koch, Kenneth C. Chu, et al.. (2014). Hypoxia promotes stem cell phenotypes and poor prognosis through epigenetic regulation of DICER. : Hypoxia promotes stem cell phenotypes and poor prognosis through epigenetic regulation of DICER.. Nature Communications. 5. 1 indexed citations

14.

Yang, Da, Yan Sun, Limei Hu, et al.. (2013). Integrated Analyses Identify a Master MicroRNA Regulatory Network for the Mesenchymal Subtype in Serous Ovarian Cancer. Cancer Cell. 23(2). 186–199. 314 indexed citations

15.

Yang, Da, Yan Sun, Limei Hu, et al.. (2013). Integrated Analyses Identify a Master MicroRNA Regulatory Network for the Mesenchymal Subtype in Serous Ovarian Cancer. Cancer Cell. 23(5). 705–705. 6 indexed citations

16.

Pecot, Chad V., Ming Li, Aaron O. Bungum, et al.. (2012). Added Value of a Serum Proteomic Signature in the Diagnostic Evaluation of Lung Nodules. Cancer Epidemiology Biomarkers & Prevention. 21(5). 786–792. 45 indexed citations

17.

Lee, Sun Joo, Sukhen C. Ghosh, Hee Dong Han, et al.. (2012). Metronomic Activity of CD44-Targeted Hyaluronic Acid-Paclitaxel in Ovarian Carcinoma. Clinical Cancer Research. 18(15). 4114–4121. 36 indexed citations

18.

Pecot, Chad V., Farideh Z. Bischoff, Julie Ann Mayer, et al.. (2011). A Novel Platform for Detection of CK+ and CK− CTCs. Cancer Discovery. 1(7). 580–586. 160 indexed citations

19.

Pecot, Chad V., George A. Calin, Robert L. Coleman, Gabriel Lopez‐Berestein, & Anil K. Sood. (2010). RNA interference in the clinic: challenges and future directions. Nature reviews. Cancer. 11(1). 59–67. 654 indexed citations breakdown →

20.

Grogan, Eric L., Stephen A. Deppen, Chad V. Pecot, et al.. (2010). Diagnostic Characteristics of a Serum Biomarker in Patients With Positron Emission Tomography Scans. The Annals of Thoracic Surgery. 89(6). 1724–1729. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact